Novavax, Inc. recently announced at the Jefferies London Healthcare Conference 2025 that it is shifting its focus from direct COVID-19 commercial operations to an expanded research and development ...

(Reuters) -Shah Capital, Novavax's second-largest shareholder, is pressing the biotech's board to pursue strategic changes, including a potential sale, and warned it could launch a proxy fight if no ...

Novavax (NVAX) rose 3.70% to close at $6.45 on Friday, snapping a seven-session losing streak, with notable drops of 3.38% and 3.50% on November 18 and 19. Novavax now expects to reach profitability ...

Welcome to Jefferies London Healthcare Conference 2025. My name is Roger Song, one of the senior analysts cover semicap biotech in the U.S. It is my pleasure to have my next fireside chat with Novavax ...

We came across a bullish thesis on Novavax, Inc. on Ridire Research’s Substack. In this article, we will summarize the bulls’ ...

Finland was the first country to offer the zoonotic avian influenza A(H5N8) vaccine manufactured by Seqirus to at-risk ...

The FDA’s top vaccine regulator outlines proposed changes to the vaccine evaluation process in an internal memo.